Combined therapy of radiofrequency ablation with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety

Combined therapy of radiofrequency ablation with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety - Combined therapy of radiofrequency ablation with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001701

Enrollment

Registered

2012-04-01

Start date

2009-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Immature dendritic cell treatment OK-432 stimulated dendritic cell treatment No cell treatment control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Advanced hepatocellular carcinoma

Exclusion criteria

Exclusion criteria: Immunodeficiency

Design outcomes

Primary

Measure	Time frame
Safety	—

Countries

Japan

Contacts

Public ContactTatsuya Yamashita

Kanazawa University University hospital

ytatsuya@m-kanazawa.jp0762652235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026